Subscribe

Recent Articles

Popular Posts

Site search

Follow Us

The Ethics of Paying to Continue a Clinical Trial

Written by on Wednesday, April 11th, 2007 Print This Post Print This Post

The Wall Street Journal ran a disturbing story today about a clinical trial that ran low on funding and has depended on payments by patients to continue. 

The clinical trial in question is an amyotrophic lateral sclerosis ("ALS") study run by James P. Bennett Jr., director of the Center for the Study of Neurodegenerative Diseases at the University of Virginia. 

Is this ethical?  According to The Wall Street Journal:

[S]eeking funds directly from patients. . . raises a number of ethical and economic questions — questions that any research effort considering such a solution would have to face. It means soliciting patients at a very vulnerable time, when they may be desperate for hope. With ALS, for instance, there is no cure; the disease attacks the nerves that control movement and usually leads to death within five years. Already struggling to pay for aspects of their own care, patients could quickly find themselves tapped out.

There is also less accountability for how money is spent when it is donated directly to a study rather than through a grant-giving nonprofit. And while Dr. Bennett has no financial interest in his ALS drug, investigators in other trials may financially benefit from their research role, causing potential conflicts of interest.
Clearly, this story is not the norm.  But I can’t help but wonder how often this scenario is arising today.  How often are patients funding their own trials?  And is that really any different than starting your own foundation and funding it to do the same thing?  Certainly, there may be more oversight in the case of a foundation, but in both scenarios, a patient is taking his health in his own hands and taking a risk in the hope of finding a cure or even a treatment for his illness. 
 
On the other hand, when the patient is acting directly to fund a trial, there is an increased risk that such patient will be taken advantage of or even coerced into paying for a treatment that has not yet been proven to work.
 
Of course, how often do patients go bankrupt paying for treatments that have only a small chance of working?  You hear stories in the news each day like this, and I even know a few people who have personally experienced such a fate.  Luckily they are still around to share their experiences.  This story is troubling on a number of levels and raises some difficult ethical issues that we should definitely be discussing, but I think that we also have to put it into its proper context before condemning what has taken place here.  What is ethical when it comes to a clinical trial, particularly in the case of a terminal disease such as ALS?   And what would you be willing to do yourself if you were the one with the unfortunate diagnosis? 

822 total views, 1 views today


© 2008-2015 The Prinz Law Office. All rights reserved.

The Prinz Law Office | Silicon Valley, CA | Los Angeles, CA | Orange County, CA | San Diego, CA | Atlanta, GA | Tel: 1.800.884.2124

Mailing Address: 117 Bernal Rd., Suite 70-110, San Jose, CA 95119; Silicon Valley Office: San Jose- 2033 Gateway Place, 5th Floor, San Jose, CA 95110 (408)884-2854; Los Angeles Office: 3110 Main St., Building C, Santa Monica, CA 90405 (310)907-9218; Orange County Office: 100 Spectrum Center Drive, 9th Floor, Irvine, CA 92618 (949)236-6777; San Diego Office: 4455 Murphy Canyon Road, Suite 100, San Diego, CA 92123 (619)354-2727 Atlanta Office: 1000 Parkwood Circle, Suite 900, Atlanta, Georgia 30339 (404)479-2470

Biotech Lawyer & Attorney: Serving Silicon Valley, San Jose, San Francisco, Santa Cruz, San Diego, Los Angeles, Orange County, Irvine, Anaheim, Santa Monica, Silicon Beach, Santa Barbara, Sacramento, Atlanta. Licensed in California and Georgia.
Follow

Get every new post delivered to your Inbox

Join other followers